002422.SZ
002422.SZ
CNE100000PW7
KELUN PHARMA
Loading chart...

Company Profile

Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, produces, and sells infusion and non-infusion pharmaceutical products in China and internationally. The company operates through Chuanning, Botai, and Other Business segments. The company offers infusion products; oral medication and other dosage form; medical devices, such as infusion sets, sterile dispensing and injection syringes, vein detained needles, nebulizer sets, and vacuum blood collection tubes; over-the-counter products; and APIs to treat cardiovascular, IPF, ED, anti-tumor, anti-emetic, antibiotic, VB12, anti-rheumatoid arthritis, multiple sclerosis, anti-schizophrenia, CKD and anti-anemia, polypeptide, and other indications. It also provides ambroxol hydrochloride, potassium chloride, sodium chloride, magnesium sulfate, glucose, sterile water, sodium bicarbonate, lidocaine hydrochloride, vitamin B6, ribavirin, ceftazidime, 5% glucose, and ceftriaxone sodium injections. In addition, the company engages in investment; import and export; enterprise management; logistics and transportation; business services; agricultural non-staple food processing; production and sale of pharmaceutical intermediates; research and development of bio-based materials technology; Internet and related services; crop planting; professional technical; biotechnology extension; socio-economic consultation; technology promotion; medical research and testing exhibition; general cargo road transport; ecological protection and environmental management; and wholesale and retail. It exports its products to Japan. The company was formerly known as Sichuan Kelun Pharmaceutical Factory Co., Ltd and changed its name to Sichuan Kelun Pharmaceutical Co., Ltd. in August 2003. The company was founded in 1996 and is based in Chengdu, the People's Republic of China. Sichuan Kelun Pharmaceutical Co., Ltd. operates as a subsidiary of Sichuan Kelun Industry Group CO., LTD.

Related stocks

600436.SS
600436.SS • China
ZHANGZHOU PIENTZEHUANG PHARMACE
119.82 CNY
10.82B USD 1Y -38.9%
1093.HK
1093.HK • China
CSPC PHARMA
9.09 HKD
13.2B USD 1Y -3.4%
4528.T
4528.T • Japan
ONO PHARMACEUTICAL CO
2,259 JPY
6.71B USD 1Y +22%
4536.T
4536.T • Japan
SANTEN PHARMACEUTICAL CO
1,684 JPY
3.42B USD 1Y +7.8%
4568.T
4568.T • Japan
DAIICHI SANKYO COMPANY LIMITED
2,623 JPY
30.16B USD 1Y -37.2%
GLAXO.NS
GLAXO.NS • India
GLAXOSMITHKLINE PHARMA LT
2,540.3 INR
4.45B USD 1Y -8%
RUBICON.NS
RUBICON.NS • India
RUBICON RESEARCH LIMITED
1,548.5 INR
2.65B USD
4503.T
4503.T • Japan
ASTELLAS PHARMA
2,247.5 JPY
25.47B USD 1Y +35.2%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
39.0% p.a.
Max Drawdown (5Y)
-31.6%
Sharpe Ratio (5Y)
0.36
Beta Factor
-0.20
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (39.0% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -58.9% in the extended horizon.
ende